DexCom, Inc. (DXCM) | Investment Case

1. Company Snapshot

1.a. Company Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

The company's products candidature comprises Dexcom G7, a next generation G7 CGM system.DexCom, Inc.has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.

The company markets its products directly to endocrinologists, physicians, and diabetes educators.DexCom, Inc.was incorporated in 1999 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on DXCM

DexCom's recent performance was driven by easing G7 issues, improving supply chains, and rebounding U.S. new customer starts, lifting revenue outlook. The company's Q4 2025 earnings beat estimates, with quarterly earnings of $0.68 per share and 13% revenue growth. Strong revenue growth and strategic expansions, including G7 15 Day rollout and margin gains, drove momentum. Institutional investors, such as Intact Investment Management Inc. and DSM Capital Partners LLC, increased their holdings in the company, signaling confidence in its growth prospects.

1.c. Company Highlights

Last Price	73.08
Change Percentage	-0.95%
Open	72.47
Previous Close	73.78
Market Cap ( Millions)	28502
Volume	2328641
Year High	89.98
Year Low	54.11
M A 50	70.21
M A 200	73.8

FCF Yield	3.78%
Dividend Yield	0.00%
ROE	32.44%
Debt / Equity	50.61%
Net Debt / EBIDTA	35.31%
Price To Book	10.29
Price Earnings Ratio	33.79
Price To FCF	26.46
Price To sales	6.11
EV / EBITDA	21.68

2. DexCom's Strong FY2025 Results Exceed Expectations

DexCom's revenue for the fourth quarter of 2025 was $1.26 billion, representing a 13% year-over-year growth, with US revenue at $892 million, up 11%, and international revenue at $368 million, up 18%. The gross profit margin expanded to 63.5% from 59.4% in 2024. The company's net income for the quarter was $265.1 million, or $0.68 per share, beating analyst estimates of $0.576. For the full year 2025, operating expenses were $4.683 billion, compared to $451.7 million in 2024.

Publication Date: Feb -13

📋 Highlights

Guidance and Outlook

The company guided for total revenue in the range of $5.16 to $5.25 billion for 2026, representing an 11% to 13% growth. Jereme M. Sylvain mentioned that the revenue growth is driven by patient base growth, retention, utilization, and price, with an expected 20% patient base growth in 2026. According to Jereme M. Sylvain, "we don't necessarily need a record new patient year to hit the low end of our guidance, but a record new patient year would be required to hit the top end of the range."

Product Updates and Expansion

DexCom's 15-day CGM system has been rolled out across all US channels, with positive initial feedback. The company is also expanding its product portfolio with Stelo and enhancing its software capabilities, including Smart Basal and meal tracking. Jacob Steven Leach highlighted the potential of Smart Basal to improve the user experience, stating that they are piloting this technology and expect it to drive more share of the patient population.

Valuation

With a P/E Ratio of 35.32 and an EV/EBITDA of 21.44, the market seems to have priced in significant growth expectations. The company's ROE is 29.82%, indicating strong profitability. The actual EPS of $0.61 beat analyst estimates of $0.576, and the revenue growth is expected to continue, with analysts estimating a 12.5% revenue growth for the next year.

Coverage Expansion

DexCom is working to expand coverage for its CGM system, particularly for type 2 non-insulin users, with a randomized control trial expected to readout in mid-2026. The company has 6 million covered lives for G7 non-intensive type 2 and is targeting additional lives through fee-for-service and Med Advantage. Jereme M. Sylvain mentioned that they have made progress in gaining market share and will continue to work on expanding coverage.

3. NewsRoom

DexCom, Inc. (DXCM) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Mar -02

Source: seekingalpha.com

111 Capital Buys 10,040 Shares of DexCom, Inc. $DXCM

Mar -02

Source: defenseworld.net

Andra AP fonden Has $6.25 Million Stock Position in DexCom, Inc. $DXCM

Mar -01

Source: defenseworld.net

DNB Asset Management AS Acquires 803,086 Shares of DexCom, Inc. $DXCM

Feb -27

Source: defenseworld.net

Dexcom Appoints Rick Osterloh to Board of Directors

Feb -26

Source: businesswire.com

HALPER SADEH LLC ENCOURAGES DEXCOM, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Feb -26

Source: prnewswire.com

Got $10,000? I Think DexCom Stock Could Be a Quiet Winner of the GLP‑1 Wars

Feb -25

Source: fool.com

Dexcom Announces Upcoming Conference Presentation

Feb -25

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.50%)

6. Segments

Patient Monitoring Equipment

Expected Growth: 15.5%

Growing demand for real-time glucose level monitoring drives growth, fueled by increasing prevalence of diabetes and advancements in wearable technology, enabling DexCom's patient monitoring devices.

7. Detailed Products

G6 CGM System

A continuous glucose monitoring system that provides real-time glucose readings every 5 minutes, with a sensor that can be worn for up to 10 days.

G6 Pro CGM System

A professional continuous glucose monitoring system designed for healthcare professionals to use with their patients, providing detailed glucose data to inform treatment plans.

Dexcom CLARITY

A diabetes management software that provides a comprehensive view of glucose data, trends, and patterns, enabling more informed decision-making.

Dexcom G4 PLATINUM CGM System

A continuous glucose monitoring system that provides real-time glucose readings every 5 minutes, with a sensor that can be worn for up to 7 days.

8. DexCom, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

DexCom, Inc. has a low threat of substitutes due to its strong brand recognition and patented technology in the continuous glucose monitoring market.

Bargaining Power Of Customers

DexCom, Inc. has a medium bargaining power of customers due to the presence of multiple competitors in the market, but its strong brand loyalty and customer retention rates mitigate this risk.

Bargaining Power Of Suppliers

DexCom, Inc. has a low bargaining power of suppliers due to its strong relationships with suppliers and the availability of multiple suppliers for its components.

Threat Of New Entrants

DexCom, Inc. has a medium threat of new entrants due to the high barriers to entry in the continuous glucose monitoring market, including regulatory hurdles and high research and development costs.

Intensity Of Rivalry

DexCom, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry in the continuous glucose monitoring market.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	55.63%
Debt Cost	3.95%
Equity Weight	44.37%
Equity Cost	10.07%
WACC	6.66%
Leverage	125.40%

11. Quality Control: DexCom, Inc. passed 6 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Abbott

A-Score: 6.3/10

Value: 2.8

Growth: 5.9

Quality: 7.8

Yield: 4.0

Momentum: 7.5

Volatility: 9.7

1-Year Total Return ->

Stryker

A-Score: 5.3/10

Value: 1.4

Growth: 6.4

Quality: 6.6

Yield: 2.0

Momentum: 5.0

Volatility: 10.0

1-Year Total Return ->

Boston Scientific

A-Score: 5.2/10

Value: 1.2

Growth: 6.6

Quality: 6.8

Yield: 0.0

Momentum: 7.5

Volatility: 9.3

1-Year Total Return ->

Thermo Fisher

A-Score: 4.8/10

Value: 1.7

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 7.0

Volatility: 7.7

1-Year Total Return ->

Danaher

A-Score: 4.3/10

Value: 1.7

Growth: 3.9

Quality: 6.8

Yield: 1.0

Momentum: 5.0

Volatility: 7.7

1-Year Total Return ->

DexCom

A-Score: 4.3/10

Value: 1.5

Growth: 9.1

Quality: 6.8

Yield: 0.0

Momentum: 3.5

Volatility: 4.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

4.46%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.66%

DexCom, Inc. - US2521311074

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on DXCM

1.c. Company Highlights

Expensive

Higher Growth

Better Quality

Earnings Beats

Revenues Beats

Average Quality

Revenues Miss

Earnings Miss

Stable Momentum

Weak Momentum

2. DexCom's Strong FY2025 Results Exceed Expectations

Guidance and Outlook

Product Updates and Expansion

Valuation

Coverage Expansion

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (15.50%)

6. Segments

Patient Monitoring Equipment

Expected Growth: 15.5%

7. Detailed Products

G6 CGM System

G6 Pro CGM System

Dexcom CLARITY

Dexcom G4 PLATINUM CGM System

8. DexCom, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: DexCom, Inc. passed 6 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

73.08$

Current Price

73.08$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA